<DOC>
	<DOCNO>NCT00107653</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety PEGASYS ( 180 microgram sc weekly ) plus ribavirin ( 1000-1200mg po daily ) treatment-naive Latino patient versus non-Latino Caucasian patient chronic hepatitis C- genotype 1 . The anticipated time study treatment 3-12 month target sample size 500+ patient .</brief_summary>
	<brief_title>Latino Study - A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) COPEGUS ( Ribavirin ) Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1 .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient 1865 year age chronic hepatitis C , genotype 1 serologic evidence CHC infection antibody test chronic liver disease , consistent CHC infection liver biopsy obtain within past 18 month compensate liver disease use 2 form contraception study men woman previous interferon ribavirin therapy systemic antiviral therapy le 24 week first dose study drug expect need treatment time study medical condition associate chronic liver disease ( eg , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure ) decompensated liver disease woman pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>